The Journal of Clinical Pharmacology
ACCP Position Papers

Edible Cannabis Products: It Is Time for FDA Oversight

David M. Benjamin PhD, FCP,

David M. Benjamin PhD, FCP

For the Public Policy Committee of the American College of Clinical Pharmacology

Search for more papers by this author
Michael J. Fossler PharmD, PhD, FCP,

Corresponding Author

Michael J. Fossler PharmD, PhD, FCP

For the Public Policy Committee of the American College of Clinical Pharmacology

Corresponding Author:

Michael Fossler, PharmD, PhD, FCP, Trevena, Inc., 1018 W. 8th Ave., King of Prussia, PA 19406

Email: mfossler@trevenainc.com

Search for more papers by this author
First published: 08 June 2016
Citations: 20
Get access to the full version of this article. View access options below.
Institutional Login
Loading institution options...
Log in to Wiley Online Library

If you have previously obtained access with your personal account, please log in.

Purchase Instant Access
    • View the article/chapter PDF and any associated supplements and figures for a period of 48 hours.
    • Article/Chapter can not be printed.
    • Article/Chapter can not be downloaded.
    • Article/Chapter can not be redistributed.
    • Unlimited viewing of the article/chapter PDF and any associated supplements and figures.
    • Article/Chapter can not be printed.
    • Article/Chapter can not be downloaded.
    • Article/Chapter can not be redistributed.
    • Unlimited viewing of the article/chapter PDF and any associated supplements and figures.
    • Article/chapter can be printed.
    • Article/chapter can be downloaded.
    • Article/chapter can not be redistributed.
First page image